skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Estimating Preferences for Treatments in Patients With Localized Prostate Cancer

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [1];  [2];  [3];  [4];  [5];  [6];
  1. Health Services Research Unit, IMIM (Hospital del Mar Medical Research Institute), Barcelona (Spain)
  2. Servicio de Oncología Radioterápica, Institut Català d'Oncologia, L'Hospitalet de Llobregat (Spain)
  3. Servicio de Urología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Spain)
  4. Servicio de Oncología Radioterápica, Instituto Oncológico de Guipúzcoa, San Sebastián (Spain)
  5. Servicio de Oncología Radioterápica, Hospital Clínico Universitario de Salamanca, Salamanca (Spain)
  6. Servicio de Oncología Radioterápica, Centro Oncológico de Galicia, A Coruña (Spain)

Purpose: Studies of patients' preferences for localized prostate cancer treatments have assessed radical prostatectomy and external radiation therapy, but none of them has evaluated brachytherapy. The aim of our study was to assess the preferences and willingness to pay of patients with localized prostate cancer who had been treated with radical prostatectomy, external radiation therapy, or brachytherapy, and their related urinary, sexual, and bowel side effects. Methods and Materials: This was an observational, prospective cohort study with follow-up until 5 years after treatment. A total of 704 patients with low or intermediate risk localized prostate cancer were consecutively recruited from 2003 to 2005. The estimation of preferences was conducted using time trade-off, standard gamble, and willingness-to-pay methods. Side effects were measured with the Expanded Prostate Index Composite (EPIC), a prostate cancer-specific questionnaire. Tobit models were constructed to assess the impact of treatment and side effects on patients' preferences. Propensity score was applied to adjust for treatment selection bias. Results: Of the 580 patients reporting preferences, 165 were treated with radical prostatectomy, 152 with external radiation therapy, and 263 with brachytherapy. Both time trade-off and standard gamble results indicated that the preferences of patients treated with brachytherapy were 0.06 utilities higher than those treated with radical prostatectomy (P=.01). Similarly, willingness-to-pay responses showed a difference of €57/month (P=.004) between these 2 treatments. Severe urinary incontinence presented an independent impact on the preferences elicited (P<.05), whereas no significant differences were found by bowel and sexual side effects. Conclusions: Our findings indicate that urinary incontinence is the side effect with the highest impact on preferences and that brachytherapy and external radiation therapy are more valued than radical prostatectomy. These time trade-off and standard gamble preference assessments as well as the willingness-to-pay estimation could be useful to perform respectively cost-utility or cost-benefit analyses, which can guide health policy decisions.

OSTI ID:
22458593
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 91, Issue 2; Other Information: Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Health-Related Quality of Life 2 Years After Treatment With Radical Prostatectomy, Prostate Brachytherapy, or External Beam Radiotherapy in Patients With Clinically Localized Prostate Cancer
Journal Article · Wed Oct 01 00:00:00 EDT 2008 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22458593

Assessing Adverse Events of Postprostatectomy Radiation Therapy for Prostate Cancer: Evaluation of Outcomes in the Regione Emilia-Romagna, Italy
Journal Article · Sun Mar 15 00:00:00 EDT 2015 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22458593

High-Dose-Rate Brachytherapy as a Monotherapy for Favorable-Risk Prostate Cancer: A Phase II Trial
Journal Article · Sun Apr 01 00:00:00 EDT 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22458593